632 related articles for article (PubMed ID: 33216043)
1. Cannabis in Parkinson's Disease: The Patients' View.
Yenilmez F; Fründt O; Hidding U; Buhmann C
J Parkinsons Dis; 2021; 11(1):309-321. PubMed ID: 33216043
[TBL] [Abstract][Full Text] [Related]
2. Cannabis in patients with Parkinson's disease in Argentina. A cross sectional study.
Micheli FE; Groppo J; Contartese ML; Baccaglio PG; Borisonik LN; Lakos C; Barros JP; Maiola RP; Arakaki T; Garretto NS; Giannaula RJ; Pecci MC
Parkinsonism Relat Disord; 2020 Sep; 78():66-67. PubMed ID: 32739838
[TBL] [Abstract][Full Text] [Related]
3. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
4. Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide study.
Trevitt BT; Bailey S; Mills L; Arkell TR; Suraev A; McGregor IS; Lintzeris N
PLoS One; 2024; 19(2):e0297092. PubMed ID: 38354169
[TBL] [Abstract][Full Text] [Related]
5. Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.
Liu Y; Bainbridge J; Sillau S; Rajkovic S; Adkins M; Domen CH; Thompson JA; Seawalt T; Klawitter J; Sempio C; Chin G; Forman L; Fullard M; Hawkins T; Seeberger L; Newman H; Vu D; Leehey MA
Mov Disord; 2024 May; 39(5):863-875. PubMed ID: 38487964
[TBL] [Abstract][Full Text] [Related]
6. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.
Szaflarski JP; Bebin EM
Epilepsy Behav; 2014 Dec; 41():277-82. PubMed ID: 25282526
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and correlates of medical cannabis patients' use of cannabis for recreational purposes.
Morean ME; Lederman IR
Addict Behav; 2019 Jun; 93():233-239. PubMed ID: 30772776
[TBL] [Abstract][Full Text] [Related]
8. Practical considerations in medical cannabis administration and dosing.
MacCallum CA; Russo EB
Eur J Intern Med; 2018 Mar; 49():12-19. PubMed ID: 29307505
[TBL] [Abstract][Full Text] [Related]
9. How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review.
Hoch E; Niemann D; von Keller R; Schneider M; Friemel CM; Preuss UW; Hasan A; Pogarell O
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):87-105. PubMed ID: 30706168
[TBL] [Abstract][Full Text] [Related]
10. Medicinal Use of Different Cannabis Strains: Results from a Large Prospective Survey in Germany.
Szejko N; Becher E; Heimann F; Grotenhermen F; Müller-Vahl KR
Pharmacopsychiatry; 2024 May; 57(3):133-140. PubMed ID: 38471525
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of Medical Cannabis.
Amin MR; Ali DW
Adv Exp Med Biol; 2019; 1162():151-165. PubMed ID: 31332738
[TBL] [Abstract][Full Text] [Related]
12. Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?
Crippa JAS; Hallak JEC; Zuardi AW; Guimarães FS; Tumas V; Dos Santos RG
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):121-133. PubMed ID: 30706171
[TBL] [Abstract][Full Text] [Related]
13. Tetrahydrocannabinol and Cannabidiol Use in an Outpatient Palliative Medicine Population.
Highet BH; Lesser ER; Johnson PW; Kaur JS
Am J Hosp Palliat Care; 2020 Aug; 37(8):589-593. PubMed ID: 31986898
[TBL] [Abstract][Full Text] [Related]
14. Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Δ9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
Domen CH; Sillau S; Liu Y; Adkins M; Rajkovic S; Bainbridge J; Sempio C; Klawitter J; Leehey MA
Mov Disord; 2023 Jul; 38(7):1341-1346. PubMed ID: 37212386
[TBL] [Abstract][Full Text] [Related]
15. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety of medical cannabis in Parkinson's disease: A retrospective case-control study.
Goldberg T; Redlich Y; Yogev D; Fay-Karmon T; Hassin-Baer S; Anis S
Parkinsonism Relat Disord; 2023 Jul; 112():105406. PubMed ID: 37211456
[TBL] [Abstract][Full Text] [Related]
17. Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience.
Balash Y; Bar-Lev Schleider L; Korczyn AD; Shabtai H; Knaani J; Rosenberg A; Baruch Y; Djaldetti R; Giladi N; Gurevich T
Clin Neuropharmacol; 2017; 40(6):268-272. PubMed ID: 29059132
[TBL] [Abstract][Full Text] [Related]
18. Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use.
Pichini S; Mannocchi G; Berretta P; Zaami S; Pirani F; Pacifici R; Busardò FP
Ther Drug Monit; 2020 Feb; 42(1):151-156. PubMed ID: 31389860
[TBL] [Abstract][Full Text] [Related]
19. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
Patti F
Neurodegener Dis Manag; 2019 Apr; 9(2s):3-7. PubMed ID: 30657027
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey.
Boehnke KF; Gagnier JJ; Matallana L; Williams DA
J Pain; 2021 May; 22(5):556-566. PubMed ID: 33400996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
